WILLIAM E WISE

Allopathic & Osteopathic Physicians|Internal Medicine WAXAHACHIE, TX NPI 1508945593

General Payments — all program years on this page

$2,083.05

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 82
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $329.94 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $329.9420

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $144.279
Lilly USA, LLC $92.446
Exact Sciences Corporation $31.022
PFIZER INC. $27.291
Astellas Pharma US Inc $21.261
GlaxoSmithKline, LLC. $13.661

By program year

Program yearAmountRecords
2018 $350.774
2019 $220.534
2020 $30.052
2021 $417.8413
2022 $240.2015
2023 $493.7224
2024 $329.9420

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096659919 Novo Nordisk Inc $14.21 01/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096714381 Novo Nordisk Inc $15.12 07/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096783997 Novo Nordisk Inc $17.53 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096910957 Novo Nordisk Inc $15.03 09/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096943948 Novo Nordisk Inc $16.00 02/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097034680 Novo Nordisk Inc $15.61 11/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097208121 Novo Nordisk Inc $19.15 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097295433 Novo Nordisk Inc $17.42 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097672326 Novo Nordisk Inc $14.20 04/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114952323 Exact Sciences Corporation $15.70 04/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114952327 Exact Sciences Corporation $15.32 08/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116206550 GlaxoSmithKline, LLC. $13.66 05/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131611260 PFIZER INC. $27.29 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135453683 Lilly USA, LLC $14.60 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135453685 Lilly USA, LLC $15.99 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135453687 Lilly USA, LLC $14.42 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135480581 Lilly USA, LLC $17.23 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135505696 Lilly USA, LLC $13.66 01/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135514990 Lilly USA, LLC $16.54 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139325008 Astellas Pharma US Inc $21.26 03/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.